Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

winthrop medicaments - nifuroxazide - suspension - 4 g - composition pour 100 g de suspension buvable > nifuroxazide : 4 g

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

zydus france - nifuroxazide - gélule - 100 mg - composition pour une gélule > nifuroxazide : 100 mg

Polen - polsk - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

aflofarm farmacja polska sp. z o.o. - nifuroxazidum - tabletki powlekane - 200 mg

Polen - polsk - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

aflofarm farmacja polska sp. z o.o. - nifuroxazidum - tabletki powlekane - 100 mg

USA - engelsk - NLM (National Library of Medicine)

stat rx usa - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride 10 mg - uroxatral is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. uroxatral is not indicated for the treatment of hypertension. the recommended dosage is one 10 mg uroxatral (alfuzosin hcl) extended-release tablet once daily. the extent of absorption of uroxatral is 50% lower under fasting conditions. therefore, uroxatral should be taken immediately after the same meal each day. the tablets should not be chewed or crushed. uroxatral (alfuzosin hcl) extended-release tablet 10 mg is available as a round, three-layer tablet: one white layer between two yellow layers, debossed with x10. uroxatral is contraindicated for use in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients. [see clinical pharmacology (12.3)]. uroxatral is contraindicated for use with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased. [see

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride 10 mg - uroxatral is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. uroxatral is not indicated for the treatment of hypertension. uroxatral is not indicated for use in the pediatric population. uroxatral is contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations (8.7) and clinical pharmacology (12.3)]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1) and clinical pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of uroxatral tablets [see adverse reactions (6.2)] pregnancy category b. uroxatral is not indicated for use in women, and there are no studies of alfuzosin in pregnant women alfuzosin was not teratogenic, embryotoxic or

USA - engelsk - NLM (National Library of Medicine)

concordia pharmaceuticals inc. - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride 10 mg - uroxatral is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. uroxatral is not indicated for the treatment of hypertension. uroxatral is not indicated for use in the pediatric population. uroxatral is contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations (8.7) and clinical pharmacology (12.3)]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1) and clinical pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of uroxatral tablets [see adverse reactions (6.2)] risk summary uroxatral is not indicated for use in women. there are no adequate data on the developmental risk associated with use of uroxatral in pregnant women. b

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

world medicine ΕΜΠΟΡΙΟ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ ΜΟΝΟΠΡΟΣΩΠΗ ΕΤΑΙΡΕΙΑ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΕΥΘΥΝΗΣ Δ.Τ. world medicine ΜΟΝ.ΕΠΕ - nifuroxazide - ΠΟΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - 220mg/5ml - 0000965526 - nifuroxazide - 44.000000 mg - nifuroxazide

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

world medicine ΕΜΠΟΡΙΟ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ ΜΟΝΟΠΡΟΣΩΠΗ ΕΤΑΙΡΕΙΑ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΕΥΘΥΝΗΣ Δ.Τ. world medicine ΜΟΝ.ΕΠΕ - nifuroxazide - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 200mg/cap - 0000965526 - nifuroxazide - 200.000000 mg - nifuroxazide

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

sanofi-aventis aebe (0000007147) Λεωφ. Συγγρού 348, Κτίριο Α’,, 176 74, Καλλιθέα, 176 74 - nifuroxazide - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 200mg/cap - 0000965526 nifuroxazide 200.000000 mg - nifuroxazide